Literature DB >> 35608753

CRISPR-Based Genome-Editing Tools for Huntington's Disease Research and Therapy.

Yiyang Qin1, Shihua Li1, Xiao-Jiang Li1, Su Yang2.   

Abstract

Huntington's disease (HD) is an autosomal dominantly-inherited neurodegenerative disease, which is caused by CAG trinucleotide expansion in exon 1 of the Huntingtin (HTT) gene. Although HD is a rare disease, its monogenic nature makes it an ideal model in which to understand pathogenic mechanisms and to develop therapeutic strategies for neurodegenerative diseases. Clustered regularly-interspaced short palindromic repeats (CRISPR) is the latest technology for genome editing. Being simple to use and highly efficient, CRISPR-based genome-editing tools are rapidly gaining popularity in biomedical research and opening up new avenues for disease treatment. Here, we review the development of CRISPR-based genome-editing tools and their applications in HD research to offer a translational perspective on advancing the genome-editing technology to HD treatment.
© 2022. Center for Excellence in Brain Science and Intelligence Technology, Chinese Academy of Sciences.

Entities:  

Keywords:  Animal models; CRISPR; Huntington’s disease

Year:  2022        PMID: 35608753     DOI: 10.1007/s12264-022-00880-3

Source DB:  PubMed          Journal:  Neurosci Bull        ISSN: 1995-8218            Impact factor:   5.203


  92 in total

Review 1.  Trinucleotide repeat disorders.

Authors:  Harry T Orr; Huda Y Zoghbi
Journal:  Annu Rev Neurosci       Date:  2007       Impact factor: 12.449

2.  CRISPR/Cas9-Mediated Genome Editing for Huntington's Disease.

Authors:  Gabriel Vachey; Nicole Déglon
Journal:  Methods Mol Biol       Date:  2018

Review 3.  Genome engineering with targetable nucleases.

Authors:  Dana Carroll
Journal:  Annu Rev Biochem       Date:  2014-03-03       Impact factor: 23.643

4.  Correlation Between CCG Polymorphisms and CAG Repeats During Germline Transmission in Chinese Patients with Huntington's Disease.

Authors:  Hong-Rong Cheng; Xiao-Yan Li; Hui-Li Yu; Miao Xu; Yan-Bin Zhang; Shi-Rui Gan; Hong-Lei Li; Zhi-Ying Wu
Journal:  Neurosci Bull       Date:  2020-03-19       Impact factor: 5.203

Review 5.  Molecular mechanisms and potential therapeutical targets in Huntington's disease.

Authors:  Chiara Zuccato; Marta Valenza; Elena Cattaneo
Journal:  Physiol Rev       Date:  2010-07       Impact factor: 37.312

Review 6.  Huntington disease.

Authors:  Gillian P Bates; Ray Dorsey; James F Gusella; Michael R Hayden; Chris Kay; Blair R Leavitt; Martha Nance; Christopher A Ross; Rachael I Scahill; Ronald Wetzel; Edward J Wild; Sarah J Tabrizi
Journal:  Nat Rev Dis Primers       Date:  2015-04-23       Impact factor: 52.329

Review 7.  Polyglutamine Repeats in Neurodegenerative Diseases.

Authors:  Andrew P Lieberman; Vikram G Shakkottai; Roger L Albin
Journal:  Annu Rev Pathol       Date:  2018-08-08       Impact factor: 23.472

8.  Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases.

Authors:  Dirk Hockemeyer; Frank Soldner; Caroline Beard; Qing Gao; Maisam Mitalipova; Russell C DeKelver; George E Katibah; Ranier Amora; Elizabeth A Boydston; Bryan Zeitler; Xiangdong Meng; Jeffrey C Miller; Lei Zhang; Edward J Rebar; Philip D Gregory; Fyodor D Urnov; Rudolf Jaenisch
Journal:  Nat Biotechnol       Date:  2009-08-13       Impact factor: 54.908

Review 9.  ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering.

Authors:  Thomas Gaj; Charles A Gersbach; Carlos F Barbas
Journal:  Trends Biotechnol       Date:  2013-05-09       Impact factor: 19.536

10.  Degeneration Versus Development: Hunting-Out the D-Unit of Huntington's Disease.

Authors:  Shengyi Lu; Boxun Lu
Journal:  Neurosci Bull       Date:  2021-03-15       Impact factor: 5.203

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.